Stryker Hits New 52-Week High - Analyst Blog
May 10 2013 - 12:15PM
Zacks
Shares of Stryker
Corporation (SYK) achieved a new 52-week high, touching
$67.36 on May 9, which is above its previous level of $67.15, and
closed at $67.01 on the same date. The closing price of this
orthopedic devices giant represented a solid one-year return of
27.7% and year-to-date return of 20.4%.
Average volume of shares traded over the last 3 months came in at
approximately 1,562K. Currently, the stock trades at a forward P/E
of 15.96x, above its peer group P/E of 14.43x.
Growth Drivers
Impressive first-quarter 2013 results, including an earnings
surprise of 1.98% and the recent completion of the acquisition of a
leading China-based trauma manufacturing company, Trauson Holdings,
were the primary growth drivers for Stryker.
On Apr 24, Stryker reported its first-quarter earnings per share of
$1.03 beating the Zacks Consensus Estimate by 2 cents and the
year-ago earnings by 4.0%. Organic revenue growth along with cost
curtailment efforts by the company’s global quality and operations
group led to the year-over-year growth.
Stryker’s strong business fundamentals, well-diversified product
portfolio and expanding foothold in emerging markets through
acquisitions are expected to drive future growth. Moreover, the
company remains committed to delivering incremental return to
investors via share repurchase and dividends.
Recently, in Mar 2013, it completed the acquisition of a leading
China-based trauma manufacturing company, Trauson Holdings. Stryker
acquired this entity in an effort to strengthen its foothold in the
Chinese orthopedic market.
Stryker, with a market-cap of $25.33 billion, is one of the world’s
largest medical device manufacturers operating in the global
orthopedic market. The recent stability in the domestic recon
market and turnaround of its European business should improve
results in 2013.
Stocks to Consider
Stryker carries a Zacks Rank #3 (Hold). With Stryker’s shares
trading at all-time highs, any upside from here may be limited.
Other medical stocks such as Conceptus (CPTS),
TG Therapeutics (TGTX) and
AtriCure (ATRC) warrant a look. While Conceptus
carries a Zacks Rank #1 (Strong Buy), the other two stocks carry a
Zacks Rank #2 (Buy).
ATRICURE INC (ATRC): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
TG THERAPEUTICS (TGTX): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024